See more : Argent BioPharma Limited (RGT.L) Income Statement Analysis – Financial Results
Complete financial analysis of Evolus, Inc. (EOLS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Evolus, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- HS GovTech Solutions Inc. (HDSLF) Income Statement Analysis – Financial Results
- Health Catalyst, Inc. (HCAT) Income Statement Analysis – Financial Results
- Evolution Technology Resources Inc. (ETKR) Income Statement Analysis – Financial Results
- Wealth Invest Allspring Small C (WEIASCA.CO) Income Statement Analysis – Financial Results
- Peridot Acquisition Corp. II (PDOT-WT) Income Statement Analysis – Financial Results
Evolus, Inc. (EOLS)
About Evolus, Inc.
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 202.09M | 148.62M | 99.67M | 56.54M | 34.93M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 61.56M | 55.89M | 43.53M | 18.30M | 8.01M | 9.00K | 218.00K | 326.00K | 416.00K |
| Gross Profit | 140.53M | 92.73M | 56.14M | 38.24M | 26.91M | -9.00K | -218.00K | -326.00K | -416.00K |
| Gross Profit Ratio | 69.54% | 62.40% | 56.32% | 67.64% | 77.05% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 6.56M | 4.74M | 2.06M | 1.72M | 3.97M | 6.49M | 6.69M | 12.61M | 20.68M |
| General & Administrative | 157.45M | 130.20M | 0.00 | 0.00 | 0.00 | 29.15M | 4.82M | 7.03M | 9.88M |
| Selling & Marketing | 7.49M | 11.64M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 164.94M | 141.84M | 112.07M | 98.19M | 113.59M | 29.15M | 4.82M | 7.03M | 9.88M |
| Other Expenses | 18.26M | 3.72M | 5.62M | 7.03M | 4.13M | -10.50M | -5.00K | -6.00K | -39.00K |
| Operating Expenses | 189.76M | 150.30M | 119.75M | 106.94M | 121.70M | 35.64M | 11.73M | 19.97M | 30.98M |
| Cost & Expenses | 251.32M | 206.19M | 163.29M | 125.24M | 129.71M | 35.64M | 11.73M | 19.97M | 30.98M |
| Interest Income | 860.00K | 119.00K | 1.00K | 635.00K | 1.84M | 203.00K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 13.83M | 9.10M | 1.40M | 10.50M | 7.95M | 863.00K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 5.87M | 4.50M | 6.31M | 7.68M | 5.01M | 9.00K | 218.00K | 326.00K | 416.00K |
| EBITDA | -41.81M | -60.72M | -39.06M | -144.75M | -92.10M | -46.13M | -11.51M | -19.64M | -30.56M |
| EBITDA Ratio | -20.69% | -40.03% | -64.49% | -104.40% | -266.22% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -49.23M | -57.58M | -63.62M | -68.70M | -94.79M | -46.14M | -11.73M | -19.97M | -30.98M |
| Operating Income Ratio | -24.36% | -38.74% | -63.82% | -121.50% | -271.40% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -12.28M | -8.99M | -2.36M | -9.87M | -6.11M | -660.00K | -5.00K | -6.00K | -39.00K |
| Income Before Tax | -61.51M | -74.32M | -46.77M | -162.94M | -105.06M | -46.80M | -11.73M | -19.97M | -31.02M |
| Income Before Tax Ratio | -30.44% | -50.01% | -46.92% | -288.18% | -300.82% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 176.00K | 95.00K | 42.00K | 77.00K | -15.03M | 65.00K | -7.25M | 93.00K | 93.00K |
| Net Income | -61.69M | -74.41M | -46.81M | -163.01M | -90.03M | -46.87M | -4.48M | -20.07M | -31.11M |
| Net Income Ratio | -30.52% | -50.07% | -46.96% | -288.31% | -257.79% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.08 | -1.33 | -0.94 | -4.83 | -3.19 | -1.92 | -0.19 | -1.08 | -1.67 |
| EPS Diluted | -1.08 | -1.33 | -0.94 | -4.83 | -3.19 | -1.92 | -0.19 | -1.08 | -1.67 |
| Weighted Avg Shares Out | 56.92M | 56.07M | 49.77M | 33.74M | 28.24M | 24.40M | 23.59M | 18.59M | 18.59M |
| Weighted Avg Shares Out (Dil) | 56.92M | 56.07M | 49.77M | 33.74M | 28.24M | 24.40M | 23.59M | 18.59M | 18.59M |
Here's Why Evolus (EOLS) Could be Great Choice for a Bottom Fisher
Evolus (EOLS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances...
Down -29.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Evolus (EOLS)
Evolus (EOLS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Evolus, Inc. (EOLS) Reports Q3 Loss, Misses Revenue Estimates
Evolus, Inc. (EOLS) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to loss of $0.19 per share a year ago.
Evolus Reports Third Quarter 2024 Results
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported financial results for the third quarter ended September 30, 2024, and provided a business update. “Our...
Evolus to Participate in Stifel 2024 Healthcare Conference
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team will present at the Stifel Healthcare Conference in New York City on Tuesday,...
Evolus Announces EU Approval of Estyme® Injectable Hyaluronic Acid Gels Under New Medical Device Regulation
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the EU Medical Device Regulation (MDR) certification was received for four unique injectable hyaluronic acid (HA)...
Will Evolus, Inc. (EOLS) Report Negative Earnings Next Week? What You Should Know
Evolus (EOLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 10,251 shares of Evolus and...
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of an aggregate of 10,845 restricted stock units (RSUs) of the company's common stock...
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in July an aggregate of 46,363 restricted stock units (RSUs) of the company's common...
Source: https://incomestatements.info
Category: Stock Reports